Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Keros Therapeutics (Nasdaq: KROS) announced that President and CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET.
A live audio webcast will be available via Goldman Sachs and an archived replay will be accessible in the Investors section of the Keros website for up to 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – KROS
In the Jun 2 session, KROS declined 3.21%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Earnings update | Negative | -8.3% | Q1 2026 results showed return to losses after prior Takeda-driven income. |
| Mar 09 | Partnership deal | Positive | +0.4% | ALS trial collaboration with Mass General under Healey ALS MyMatch program. |
| Mar 09 | Clinical data update | Positive | +0.4% | Additional Phase 1 rinvatercept data showing tolerability and biomarker effects. |
| Mar 04 | Earnings update | Mixed | -15.0% | Q4 and 2025 results with net income driven by Takeda license revenue. |
| Feb 26 | Board change | Neutral | -5.6% | Appointment of Charles Newton and departure of Carl Gordon from board. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows negative price reactions to earnings updates and modest or negative moves around other corporate events, suggesting a cautious market stance toward the story.
Over the last several months, Keros reported earnings on Feb 26, 2026 and May 14, 2026, both followed by notable declines of -14.96% and -8.34%, respectively. A management change on Feb 26, 2026 also saw a -5.59% move. In contrast, partnership and clinical updates on Mar 9, 2026 produced only a small positive reaction of 0.44%. Against this backdrop, today’s conference participation announcement fits a pattern of informational, lower-impact news versus prior financial and pipeline catalysts.
Key Terms
transforming growth factor-beta medical
tgf-ß medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time.
A live audio webcast of the fireside chat presentation will be available at https://cc.webcasts.com/gold006/060826a_js/?entity=146_YVQJ8LJ and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
